Results from phase 2 trials showed reductions in proteinuria and eGFR improvement or stabilization over up to 52 weeks of treatment.32, 33, 34 In the phase 2 randomized controlled NOBLE trial of pegcetacoplan in posttransplant recurrent C3G or primary IC-MPGN patients (NCT04572854), all pegcetacoplan-treated patients achieved normal-or-higher serum C3 and reduced sC5b-9 levels,32,33 whereas 55% (6/11) and 33% (3/9) of patients demonstrated no glomerular C3 staining and absent electron microscopy deposits, respectively, at 52 weeks.33 This evidence concerns the gene C3 and complement 3 glomerulopathy.